Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)

Conclusions
MS disease activity is adequately controlled with personalised natalizumab EID. Interval extension to a drug trough concentration of 5 µg/mL is likely a safe target to extend natalizumab treatment intervals >6 weeks.

Trial registration number
NCT04225312.

Source: Journal of Neurology, Neurosurgery and Psychiatry - April 12, 2024 Category: Neurosurgery Authors: Toorop, A. A., van Lierop, Z. Y., Gelissen, L. M., Hoitsma, E., Zeinstra, E. M., van Rooij, L. C., van Munster, C. E., Vennegoor, A., Mostert, J. P., Wokke, B. H., Kalkers, N. F., Hoogervorst, E. L., van Eijk, J. J., Roosendaal, C. M., Kragt, J. J., Eurel Tags: Editor's choice Multiple sclerosis Source Type: research